Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) put out an update on its RESOLVE study this week, and the results look encouraging, at least at this stage. The company shared new tissue and symptom data from patients treated with EP-104GI for eosinophilic esophagitis, a condition that remains difficult to treat long term.
What stands out most is how long the effects appear to last after a single treatment.
Tissue Improvements Hold Up Over Time
In the highest dose group, patients showed large improvements in esophageal tissue health by week 12. According to the scoring system used in the study, the changes were close to what would be considered normal tissue. It is a small group, but the response was noticeably stronger than what was seen at lower doses.
Patients in the mid-dose groups also seemed to hold on to their tissue improvements much longer than expected. At 36 weeks, those improvements were still there, which is not something typically seen with existing therapies.
There also appears to be a dose relationship across the study. As doses increased, so did the level of improvement. That is something investors usually want to see in early clinical work.
Symptoms Improve Alongside Tissue Health
The company also shared updates on symptom relief, focusing on swallowing difficulty, which is a major issue for EoE patients. Among those who received treatment across most of the esophagus, more than half met the study’s definition of clinical remission at three months.
What is interesting is that many of those patients stayed in remission for much longer. At six months, most were still doing well. Even at one year, a majority of the small group still met remission criteria.
This matters because symptom relief without tissue improvement, or the other way around, tends to raise questions. Here, both seem to be moving in the same direction.
Safety So Far Looks Clean
On the safety side, nothing unexpected showed up. There have been no serious adverse events reported so far, and no cases of oral candidiasis, which can be an issue with steroid-based treatments. The drug has been described as well tolerated across all dose levels, including the highest one.
More than 200 patient-months of follow-up have now been collected, which adds some weight to the safety discussion, even though this is still early.
Why This Could Matter
EoE is a chronic disease, and current treatments usually require frequent dosing or ongoing therapy. Eupraxia’s approach is different. EP-104GI is injected directly into the esophageal wall and designed to release slowly over time.
If future studies confirm that one treatment per year can control both symptoms and inflammation, that would be a meaningful change in how the disease is managed.
What Comes Next
The randomized Phase 2b portion of the RESOLVE trial is already enrolling patients. Top-line results are expected in the third quarter of 2026. Until then, the company has said more data from the open-label part of the study will be released.
Takeaway
This is still early clinical data, and the patient numbers are small. That said, the durability being reported here is hard to ignore. Sustained tissue improvement, symptom relief, and a clean safety profile are all things investors look for at this stage.
The next real test will be whether these results hold up in the controlled Phase 2b study.
